Haidong Zhu, W. Fan, Chang Zhao, S. Wang, Yuliang Li, Zhi-Cheng JIN, Zhe-Wei Zhang, Jin-He Guo, Hong-Tao Cheng, Qi Zhang, Jian Lu, Y. J. Zeng, Weifu Lv, Hao Xu, Haibo Shao, Weiguo Xu, Xu-Ya Zhao, Shanzhi Gu, Hailan Lin, Wenheng Zheng, Longzhen Piao, Yusheng Song, Jianbo Zhao, Yuan-Cheng Wang, Zhi-guo Hou, Ying Sun, Ni Guan, Ming Huang, Weizhu Yang, Jiansong Ji, G. Teng
PURPOSE: Transarterial chemoembolization (TACE) alone has shown limited efficacy in improving survival among patients with unresectable hepatocellular carcinoma (HCC). This phase II trial compared TACE combined with camrelizumab (anti-PD-1 antibody) and rivoceranib (vascular endothelial growth factor receptor 2 inhibitor) versus TACE in unresectable HCC. METHODS: Patients with unresectable HCC (Barcelona Clinic Liver Cancer stage A to C without extrahepatic metastases) and Child-Pugh class A liver function were randomly assigned (1:1), stratified by macrovascular invasion, previous tyrosine kinase inhibitor treatment, and number of previous TACE procedures, to receive TACE combined with camrelizumab (200 mg once every 3 weeks) and rivoceranib (250 mg once daily; TACE-C-R) or TACE alone. The primary end point was progression-free survival (PFS) per composite criteria (progression per Response Evaluation Criteria in Cancer of the Liver version 5, transient deterioration to Child-Pugh class C, or TACE failure or refractoriness) in the intention-to-treat population. RESULTS: < .001). Grade ≥3 treatment-related adverse events occurred in 74.5% (70 of 94) of patients with TACE-C-R and 22.3% (23 of 103) of patients with TACE, with the most common being increased AST (29 [30.9%] and 13 [12.6%]) and increased ALT (23 [24.5%] and 14 [13.6%]). CONCLUSION: The addition of camrelizumab and rivoceranib to TACE showed statistically significant improvement in PFS for patients with unresectable HCC, with a manageable safety profile. Follow-up for further overall survival analysis is ongoing.